Granulomatosis with polyangiitis presenting with rare urogenital involvement: a case based review Authors: Natalia Muklewicz, Ilona Tadulewicz, Iwona Aponowicz, Katarzyna Sienkiewicz, Michał Kujach, Michał Chmielewski, Anna Masiak Published: 2026 ABSTRACT AbstractGranulomatosis with polyangiitis (GPA) is a rare systemic necrotizing vasculitis, typically involving the upper and lower respiratory tract and kidneys. Urogenital manifestations are uncommon (< 2%) and frequently mimic malignancy. We describe a female patient in whom GPA initially presented with urogenital manifestations and review the available literature regarding urogenital involvement in the course of GPA. We describe the case of a 58-year-old woman with granulomatosis with polyangiitis initially presenting as a bladder mass, leading to radical cystectomy before the autoimmune etiology was recognized. Over time, the disease evolved to include typical manifestations. Despite multiple relapses under conventional immunosuppression therapy, sustained remission was achieved with rituximab. A literature search of PubMed, Scopus, Embase and Directory of Open Access Journals was performed using predefined keywords related to GPA and urogenital involvement. Exclusion criteria included article language other than English, male patients and kidney involvement. Data were extracted on clinical presentation, diagnostic approach, treatment, and outcomes. We identified 40 female patients with GPA involving the urogenital tract, including our case. The cervix (45%), bladder, and urethra were the most commonly affected sites. In 48 of cases, urogenital involvement was the first manifestation of GPA, frequently mimicking gynecologic or urologic malignancy. Unnecessary surgical interventions were reported in 43% of patients. Corticosteroids and cyclophosphamide were the most commonly used therapies, while rituximab was effective in refractory disease. Urogenital involvement in GPA is rare, often misdiagnosed as malignancy, and associated with significant diagnostic and therapeutic challenges. Heightened awareness of this atypical presentation and early rheumatologic evaluation is crucial to prevent unnecessary invasive procedures. Rituximab represents an effective treatment option in relapsing or refractory cases.Supplementary InformationThe online version contains supplementary material available at 10.1007/s00296-026-06197-y.Keywords: Granulomatosis with polyangiitis, Urogenital involvement, Bladder mass, Rituximab Introduction Granulomatosis with polyangiitis (GPA) is a rare ANCA-associated vasculitis characterized by necrotizing granulomatous inflammation predominantly affecting the upper and lower respiratory tract and kidneys [1, 2]. Proteinase 3 antineutrophil cytoplasmic antibodies (PR3-ANCA) are detected in the majority of patients and constitute an important diagnostic biomarker [3]. However, GPA may occasionally present with limited or atypical organ involvement, which can significantly delay diagnosis and appropriate treatment. Urogenital involvement in GPA is uncommon and rarely represents the initial or dominant manifestation of the disease [4]. In particular, inflammatory infiltrative lesions of the pelvis and urinary tract may clinically and radiologically mimic malignancy, leading to extensive diagnostic procedures and unnecessary surgical interventions. Due to the rarity of such presentations, diagnosis may be especially challenging in patients without typical respiratory or renal manifestations. Herein, we report a rare case of limited GPA initially presenting as an infiltrative pelvic mass involving the urinary bladder and adjacent urogenital structures, closely resembling a neoplastic process. The diagnosis was established only after extensive histopathological and immunological evaluation, while typical systemic manifestations of GPA developed several years later. This case highlights the diagnostic difficulties associated with atypical urogenital GPA and emphasizes the importance of considering vasculitis in the differential diagnosis of inflammatory pelvic tumors. In addition, we discuss this uncommon presentation in the context of the available literature to summarize current evidence regarding diagnostic challenges and therapeutic approaches in urogenital GPA. This study was conducted and reported in accordance with the CA-se-BA-sed RE-view sTandards (CABARET) [5]. Case presentation In June 2017, a 58-year-old female patient was admitted to the Department of Rheumatology for further evaluation of granulomatosis with polyangiitis (GPA) with an atypical clinical manifestation involving the urogenital tract. The chronological course of the disease, including clinical manifestations, diagnostic findings, treatment, and outcomes, is summarized in Table 1. Table 1The chronological course of the disease, including clinical manifestations, diagnostic findings, treatment and outcomesDateClinical manifestationImaging findingsHistopathology resultsLaboratory/ImmunologicDifferential diagnosesTreatmentOutcome2015 Jun–JulPelvic pain; pelvic mass infiltrating bladder and left ureterCT pelvis: irregular mass from vaginal cuff with invasion of bladder wallTURBTiS: chronic cystitis, no malignancy–/not significantBladder cancerTURBTiS:Symptoms persisted; progression on imaging2015 OctPersistent pelvic pain and urinary symptomsProgression of infiltrative pelvic changesBricker cystectomy: chronic inflammation with granulomatous and necrotizing lesions; focal venous thrombosis, reactive fibroblast proliferation, perivesical fibrosis–/not significantBladder cancer; inflammatory pseudotumor; infections (bacterial, fungal); actinomycosisBricker cystectomy with urostomyPostoperative complications: hydronephrosis, lymphocele2015–early 2017Recurrent vaginal stump inflammation; multiple hospitalizations; sepsisProgression of infiltration of vaginal vestibule, urethra, and labiaLabia majora biopsy: chronic focal inflammation, no malignancy–/not significantVulvar dysplasia/neoplasia; infections (bacterial, fungal); actinomycosisAntibiotics; supportive careRecurrent inflammation and complicationsJun 2017Perineal and articular pain; labial edema; mucosal ulcerations. AnemiaCT chest, ENT exam, upper airway imaging: no abnormalitiesPrevious specimens: Granulomatous inflammation and vasculitis. Gastroscopy: chronic atrophic gastritis; anti-parietal cell ATPase Ab+ (Addison-Biermer disease)Normocytic anemia; ↑CRP; ↑ESR; c-ANCA (PR3+++); ANA positive (cytoplastic); Anti-PM-Scl100 low level; RF and anti-CCP negative; IgG4 normalInfections; malignancy; IgG4-related disease; systemic autoimmune diseasesIV methylprednisolone → oral prednisone; IV cyclophosphamideRemission achieved; maintenance methotrexateDec 2020Relapse: epistaxis, purpuric skin lesions, fever, neuropathyNot specified–/not significant↑CRP; ↑D-dimer; ↑creatinine; PR3-ANCA > 200; anemia; thrombocytosisDisease relapse; infections; other vasculitidesIntensified steroids + IV cyclophosphamide x6Clinical improvement. Methotrexate continued as maintenanceApr, Jun, Sep 2022Exacerbations: sinusitis, facial edema, purpura, arthritis, purulent-bloody nasal discharge, mucosal ulcersNot specified–/not significant–/not significantInfectious etiologies; relapse; other systemic autoimmune diseasesGlucocorticoids + cyclophosphamideRelapsing course; limited responseNov 2022 onwardPersistent inflammatory activityNot specified–/not significant–/not significantRefractory GPARituximab (induction + maintenance)Marked improvement; sustained remissionGPA granulomatosis with polyangiitis, CT computed tomography, ENT ear, nose, throat; c-ANCA cytoplasmic ANCA, PR3 proteinase 3, ANA antinuclear antibodies, RF rheumatoid factor, anti-CCP anti-cyclic citrullinted peptide, ESR erythrocyte sedimentation rate, CRP C-reactive protein The chronological course of the disease, including clinical manifestations, diagnostic findings, treatment and outcomes GPA granulomatosis with polyangiitis, CT computed tomography, ENT ear, nose, throat; c-ANCA cytoplasmic ANCA, PR3 proteinase 3, ANA antinuclear antibodies, RF rheumatoid factor, anti-CCP anti-cyclic citrullinted peptide, ESR erythrocyte sedimentation rate, CRP C-reactive protein The patient’s initial symptoms had developed approximately two years earlier, when pelvic pain prompted an ultrasound examination that revealed a pelvic mass infiltrating the bladder and left ureter. Subsequent contrast-enhanced pelvic CT confirmed an irregular mass arising from the vaginal cuff, with direct invasion of the urinary bladder wall (Fig. 1). In July 2015, transurethral resection of a bladder tumor in situ was performed. Histopathological examination showed chronic cystitis, with no evidence of malignancy. However, because of persistent symptoms, progression of the infiltrative lesions on imaging, and ongoing clinical suspicion of bladder cancer, a Bricker cystectomy with urostomy was performed in October 2015. Histological examination of the excised bladder demonstrated extensive chronic inflammation and granulomatous lesions within the mucosa, accompanied by focal venous thrombosis, reactive fibroblast proliferation with vimentin positivity, and perivesical fibrosis (Fig. 2). The inflammatory infiltrate was rich in CD3-positive T lymphocytes and contained necrotizing granulomas. Following surgery, hydronephrosis and a lymphocele were diagnosed in November 2015. Contrast-enhanced computed tomography (venous phase) showing an irregular soft-tissue mass (arrows) arising from the vaginal cuff, with enhancement and invasion of the urinary bladder wall. A Transverse plane. B Coronal plane. C Axial plane Representative histopathological findings in the excised urinary bladder specimen. Hematoxylin and eosin staining. Original magnification: A and C, ×20; B, ×40; D, ×10. A Marked fibroinflammatory remodeling of the bladder wall stroma with dense chronic inflammatory infiltrates (arrows). A focal neutrophil-rich microabscess is present within a disrupted vascular-like structure, suggestive of vascular wall injury (asterisks). B High-power view showing dense plasma cell-rich lymphoplasmacytic inflammatory infiltrates (arrows). C Mixed inflammatory infiltrates with plasma cells and scattered eosinophils (arrows). D Broad areas of geographic necrosis (asterisks) surrounded by active fibroinflammatory remodeling and chronic inflammatory infiltrates (arrows) Over the subsequent months, the patient required multiple hospitalizations because of recurrent inflammation of the vaginal cuff. She had previously undergone total hysterectomy with adnexectomy for uterine fibroids. At the beginning of 2017, the inflammatory process was complicated by sepsis. Because vulvar dysplasia was suspected, a biopsy of the labia majora was performed; histology revealed chronic focal inflammation, with no evidence of malignancy. During the diagnostic work-up, bacterial and fungal infections, as well as actinomycosis, were excluded. Imaging studies showed progression of the infiltrative pelvic lesions, with involvement of the vaginal vestibule, urethra, and labia (Fig. 3). Magnetic resonance imaging performed 2 years after cystectomy demonstrating a recurrent soft-tissue mass (arrows) arising from the vaginal cuff. The lesion is hypointense on T1-weighted images and shows heterogeneous signal intensity on T2-weighted images, with heterogeneous peripheral contrast enhancement. A T1-weighted image. B T1-weighted image after contrast administration. C T2-weighted image. D T2-weighted image with fat suppression In June 2017, because of arthralgia, persistent inflammation, and unclear etiology of the pelvic infiltrative lesions, the patient was referred for rheumatological consultation. Laboratory tests revealed normocytic anemia, elevated C-reactive protein and erythrocyte sedimentation rate, high-titer cytoplasmic ANCA with strong PR3 positivity, and positive antinuclear antibodies with a cytoplasmic pattern. ANA immunoblotting detected low-level anti-PM-Scl100 antibodies. Rheumatoid factor and anti-cyclic citrullinated peptide antibodies were negative, and serum IgG4 concentration was within the normal range (Table 2). Contrast-enhanced chest CT performed with a high-resolution protocol showed no evidence of pulmonary involvement. Otolaryngological examination and upper airway imaging were unremarkable. Taken together, the clinical and immunological findings supported the diagnosis of limited GPA. Table 2Laboratory findings on admissionParameterValueNormal rangesHemoglobin9,8 g/dl12–16 g/dlMCV82,4 fl80–100 flESR66 mm/h0–20 mm/hCRP38 mg/l< 5 mg/lANCA1:80 cANCAnegativeANA HEp2 antibodies1:1000Negative < 1:100ANA profilenegativenegativeRFnegativenegativeanti-CCPnegativenegative Laboratory findings on admission At the time of referral, the patient reported severe perineal pain and arthralgia, predominantly involving the shoulders and small joints of the hands. Physical examination revealed edema of the labia majora, mucosal ulcerations in the perineal region, and varicosities of the right lower limb. Inflammatory markers remained elevated (Table 2). Gastroscopy, performed as part of the evaluation of anemia, showed chronic atrophic gastritis, and the presence of anti-parietal cell ATPase antibodies confirmed pernicious anemia, consistent with Addison–Biermer disease. In the absence of clinical evidence of active infection, immunosuppressive therapy was initiated. The patient received intravenous methylprednisolone pulses at a total cumulative dose of 3000 mg, followed by oral prednisone at 1 mg/kg body weight and intravenous cyclophosphamide at 1050 mg, corresponding to 15 mg/kg body weight according to the EUVAS regimen. After six cyclophosphamide infusions, clinical remission was achieved, and methotrexate was introduced as maintenance therapy. Remission was maintained until December 2020, when the disease relapsed with new involvement of more typical GPA sites. The relapse manifested with nasal, cutaneous, and peripheral nervous system involvement, including motor neuropathy. The patient reported purpuric lesions on the limbs (Fig. 4), epistaxis, and recurrent fever. Laboratory findings showed elevated CRP, D-dimer, creatinine, and PR3-ANCA levels, together with anemia and thrombocytosis. The patient received intensified glucocorticoid therapy and six intravenous cyclophosphamide pulses according to the EUVAS protocol, with a cumulative dose of 5.4 g adjusted for renal function, resulting in clinical improvement. Methotrexate was again used as maintenance therapy. Despite this treatment, further exacerbations occurred in April, June, and September 2022. The patient was hospitalized in the Department of Otolaryngology with acute sinusitis, facial and periorbital edema, purpura, ankle arthritis, purulent-bloody nasal discharge, and ulcerative cutaneous and mucosal lesions. Owing to the relapsing disease course and limited response to previous therapies, biological treatment with rituximab was initiated in November 2022. Induction consisted of four weekly infusions, followed by maintenance infusions every six months. After three months of rituximab therapy, marked clinical improvement was observed. The patient achieved sustained remission, with only intermittent low-grade symptoms, including arthralgia of the hands and feet, low-grade fever, plantar burning sensation, nasal dryness, alopecia, and onychomycosis. No further episodes of hemorrhagic nasal discharge, mucocutaneous ulceration, skin lesions, or infections were observed. She continues to receive rituximab maintenance therapy and remains under regular rheumatological follow-up. Lesions on the skin of the limbs in december 2020 Search strategy The presented case report is supported by a literature review consistent with a narrative review. A literature search for patients with GPA manifesting as infiltration of the urogenital system was carried out using PubMed, Scopus, Embase and Directory of Open Access Journals with no time limit, completed in May 2026. The search was conducted using the following key words : (“Granulomatosis with Polyangiitis” [MeSH] OR “Granulomatosis with Polyangiitis”) AND (“Urogenital System” OR “Urogenital Tract” OR “cervix” OR “uterus” OR “vagina” OR “vulva” OR “ovary” OR “adnexa” OR “adnexal” OR “gynecologic disease” OR “female genital tract tumor” OR “urinary bladder”). Articles reporting kidney involvement as the sole manifestation within the urogenital tract were excluded. Hand-searching of citations was carried out on case series and reviewed studies to allow us to identify references that might have been missed in previous searches. Using a combination of these search terms, we undertook a review of the literature published in English, limited to full-text publications of original articles, letters to the editor and case reports in peer-reviewed journals. Exclusion criteria were other language, renal manifestations, or male patients. As the primary objective of this study was to analyze GPA presenting with involvement of female pelvic organs, the literature review was restricted to female patients. Male urogenital manifestations and isolated renal disease were excluded in order to maintain clinical relevance to the presented case and improve the consistency of the analyzed cohort. The results are presented in Table 3. Table 3Literature review of female patients with GPA and urogenital involvement.AuthorAgeGenitourinary organ involvedSymptomsOther organ involvementGenitourinary tract as the first manifestation of GPAANCA statusTreatmentThis case, 202658Bladder, vaginaBladder mass (USG), vaginal stump inflammation, perineal pain, mucosal ulcerationsENT (ear, nose, sinuses), joints, skin, peripheral nervous systemYesPositive (c-ANCA)TURBT, Bricker cystectomy with urostomy; methylprednisolone, prednisone, cyclophosphamide, methotrexate, azathioprine, rituximab Xu et al., 2026 [6]74Cervix, uterusVaginal bleeding, “cauliflower-like” erosions and vaginal wall ulcersENT (nose, mastoid process, sinuses), lungs, eye, toeNo (occurred during glucocorticoid tapering for prior GPA organ involvement)Positive (c-ANCA)High-dose glucocorticoids, rituximab Živanović et al., 2025 [7]21Vulva – labia majora/minora and vaginal introitusVulvar erosions, edema, pain, foul-smelling, necrotic discharge, near-complete detachement od the right labia mnora due to tissue necrosisENT (ear, mastoid process, sinuses), kidneys, skin, spleenYesPositive (c-ANCA)Corticosteroids, methylprednisolone, methotrexate, rituximab, epithelialization Zia et al., 2025 [8]59Vulva, vaginaPelvic pain, vaginal bleeding, rectovaginal fistulanot mentionedNo, 4 years after GPA diagnosisNot mentionedAntibiotics, rituximab, colostomy Yin et al., 2025 [9]50UterusAbdominal pain, pus vaginal discharge, mass in the left wall of the uterus (MRI)ENT (nose, sinuses), lungsyesPositive (c-ANCA)Transabdominal hysterectomy and right ovariectomy, glucocorticosteroids Song et al., 2024 [10]62Vaginal stump (patient underwent hysterectomy earlier in life) Mass at the vaginal stump, upper ureteral dilation, and bilateral hydronephrosis (pelvic CT)ENT (sinuses), lungs, kidneys, skinYes (along with cutaneous abscesses and ulcers)Positive (c-ANCA)Methylprednisolone, prednisone, rituximab Mikami-Saitoh et al., 2023 [11]72Cervix, vaginaHypermetabolic focuses in uterus cervix (PET-CT), a necrotizing granuloma in the vaginal formix (MRI)lungsNoNegativeRight upper lobectomy, segmentectomy of the left S8 and S9, hysteroscopy, prednisolone Mohanty et al., 2023 [12]19Urethra, bladder neckUrinary urgency, urinary frequency, urinary incontinence, a firm mass adjacent to the urethral orifice, a necrotic-appearing mass infiltrating the urethra and extending to the bladder neck (MRI)ENT (nose, sinuses), lungs, kidneys, joints, skinYesPositive (c-ANCA)TURBT, cystourethroscopy; methylprednisolone, prednisone, cyclophosphamide, rituximab, avacopan Gantayet et al., 2023 [13]83Cervix, uterus, ovaries, fallopian tubesAdnexal mass with mesenteric thickening and pelvic lymphadenopathy (CT)ENT (ear, sinuses), lungs, skinNoNegativeTotal abdominal hysterectomy and salpingo-oophorectomy, methylprednisolone, cyclophosphamide, azathioprine, prednisone Nowak et al., 2022 [14]36Vulva - left labium minusPain, persisting itching, rapid growth of the lesion, unpleasant odorENT (nose), lungs, kidneys, joints, skin, trachea, larynxNo, 8 years after GPA diagnosisPositive (c-ANCA)Surgical removal of the lesion; methylprednisolone, cyclophosphamide Schminke et al., 2022 [15]48Appendages: ovary, fallopian tube, periadnexal soft tissueLower abdominal pain, a complex mass of the left adnex (USG)ENT (nose), lungs, joints, eyes, skin, submandibular glandYes, but along with general symptoms and other organ involvementPositive (c-ANCA)Laparoscopic adnexectomy, high-dose glucocorticoids, cyclophosphamide, rituximab Pereira et al., 2022 [16]75Vagina, bladder, left ureterPelvic pain, intermittent hematuria, vaginal bleeding, pelvic mass (CT)noYesNot mentionedCystoscopy, ureteral stent placement, prednisone, methotrexate, rituximab Jeong et al., 2021 [17]54AdnexaA pelvic mass (CT), mass in the left adnexa (MRI)LungsYesPositive (c-ANCA)Laparoscopic removal of the adnexal mass, immunosuppressive agents Paxton et al., 2021 [18]25CervixCervical discharge, vaginal bleeding: a large irregular cervical ectropion with vaginal wall extensionENT (sinuses), lungs, kidneysNo (3rd relapse)Positive (c-ANCA)Prednisolone, cotrimoxazole, azathioprine, cyclophosphamide, mycophenolate, rituximab Bielejewska et al., 2020 [19]48OvaryLumbosacral pain, left hydronephrosis with dilation of the left ureter (CT, MRI), feverENT (nose), lungs, kidneys, skinYesPositive (c-ANCA, p-ANCA)Left nephrostomy, laparoscopic adnexectomy, methylprednisolone, prednisone, cyclophosphamide, plasmapheresis, G-CSF Ahmed et al., 2019 [20]64Urethra, bladderLower abdominal pain, dysuria, urinary hesitancy, supra-pubic fullness due to a distended urinary bladder, non-specific irregular thickening of the urinary bladder (CT)ENT (ear, nose, sinuses)NoPositive (c-ANCA)Methyloprednisolone, prednisone, cyclophosphamide, azathioprine Soro Marín et al., 2017 [21]62Urethra, vagina, vesico-vaginal fistulaVaginal bleeding, bladder tenesmus, abdominal pain, mass with crenulated margins in the urethra and vagina (CT, MRI)noYesPositive (c-ANCA)Prednisone, methotrexate, azathioprine Anderson et al., 2017 [22]36Urethra, bladder neckObstruction and acute urinary retention, gradual decrease in urinary flow, pelvic pain, hematuriaENT (sinuses), lungs, jointsNo, 6 years after GPA diagnosisPositive (c-ANCA)Urinary catheter placement, cystourethroscopy, prednisone, methotrexate, rituximab Fallahi et al., 2016 [23]33Uterus, cervixLower abdominal pain, abnormal uterine bleeding, enlarged uterus due to a heterogeneous lesion (CT)ENT (nose, sinuses), lungs, skin, oral mucosaYesPositive (c-ANCA)Hysterectomy; methylprednisolone, cyclophosphamide Campochiaro et al., 2015 [24]55CervixMetrorrhagia, cervical mass (MRI), tracer accumulation in the cervix (PET)ENT (nose), lungs, joints, skinYesPositive (c-ANCA)Methylprednisolone, prednisone, cyclophosphamide, rituximab Bastone et al., 2015 [25]34Cervix, upper vaginaMetrorrhagiaENT (sinuses), joints, skinNo (isolated relapse)Positive (c-ANCA)Methotrexate, rituximab Caron et al., 2014 [26]48CervixBleeding after sexual intercourse, mass in the cervixENT (ear, throat), lungs, tracheaYesPositive (c-ANCA)Prednisone, methotrexate Nan et al., 2014 [27]58Ovaries, cervixVaginal bleeding, ovarian cysts, abdominal nodulesENT (nose), lungs, central nervous system, carotid arteriesYesPositive (c-ANCA)Laparotomy, methylprednisolone, cyclophosphamide Oladipo et al., 2011 [28]71CervixPostmenopausal bleeding, exophytic growth on the cervix, vault granulomaENT (nose)YesPositive (c-ANCA)Hysterectomy, azathioprine Hooda et al., 2011 [29]70BladderAnemia due to haematuria, small papillary lesions (cystoscopy)LungsYesPositive (c-ANCA)Corticosteroids, cyclophosphamide Mukherjee et al., 2011 [30]42CervixIntermenstrual bleeding; the same symptom during the flare several years laterENT (nose, septum), joints, eyeYesPositive (c-ANCA)Prednisone, azathioprine, cyclophosphamide, methotrexate, rituximab Maina et al., 2009 [31]64CervixVaginal bleeding, increasing breathlesnessENT (ear), kidneys, eyes, tracheaNo, 10 years after GPA diagnosisMarginal (c-ANCA)Prednisone, cyclophosphamide Hendrix et al., 2009 [32]82CervixVaginal bleedingLungsYesPositive (c-ANCA)Prednisone, cyclophophamideBean et al., 2007 [33]32CervixVaginal bleedingENT (nose, sinuses), lungsNoPositive (c-ANCA)Prednisone, cyclophophamide Ahson et al., 2002 [34]80CervixPostmenopausal bleedingKidneysNo, 3 years after GPA diagnosisPositive (c-ANCA)Surgery, biopsy; patients died a few days laterLewis et al., 2002 [35]54VulvaVulvar soreness, contact bleedingENTNoNo data availableNo data available Malamou-Mitsi et al., 2000 [36]45CervixVaginal bleedingNot mentionedNo, 15 years after GPA diagnosisPositive (c-ANCA)Prednisone, cyclophosphamide Stone et al., 1997 [37]55CervixVaginal bleedingENT (saddle nose), lungsNoPositive (c-ANCA)Prednisone, cyclophosphamideHuong et al., 1995 [38]69UretherAnuriaENT (ear, nose), lungs, kidneys, jointsNoNot mentionedBilateral ureteral double J stents, prednisone, cyclophosphamide, plasmapheresis61BladderUrinary frequency, dysuria, hematuria, bladder pseudotumor (CT, cystoscopy)ENT (ear, nose, sinuses), lungs, eye, peripheral nervous systemNoNegativeTURB, prednisone, cyclophosphamide, azathioprine Hansen et al., 1990 [39]85BladderRecurrent cystitis, hematuriaENT (sinuses), lungsNo, 7 years after the GPA diagnosisNegativeTURB Jensen et al., 1982 [40]25Urethra, urethro-vaginal fistulaBloody discharge, urinary incontinence, dysuriaNoYesNot mentionedSurgery, prednisone Fowler et al., 1979 [41]56Urethra, bladderDysuria, urethral dischargeENT (sinuses), lungsNoNot mentionedPrednisone, cyclophosphamide Austin et al., 1978 [42]61Fallopian tubes–Lungs, kidneys, joints, eyes, adrenal caps, spleen, skeletal musclesNoNot mentionedNot mentionedFriedmann et al., 1964 [43]61CervixGynecological complaintENT (ears, nose), eyesNoNot mentionedPrednisone Literature review of female patients with GPA and urogenital involvement. Review of the pertinent literature Our literature review identified 40 female patients [6–43], including the present case, with a mean age of 55 years, with GPA involving urogenital tract. One case study could not be comprehensively described due to restricted access to the full text; consequently, the analysis relied exclusively on information available in the abstract and secondary reviews [35]. Urogenital manifestations represented the initial presentation of GPA in 19 patients (48%) [7, 9, 10, 12, 15–17, 19, 21, 23, 24, 26–30, 32, 40], highlighting that genitourinary symptoms may precede the development of more typical systemic manifestations and contribute to diagnostic delay. In contrast, most patients eventually developed classical GPA involvement, most commonly affecting the ear–nose–throat (ENT) region (73%) [6, 7, 9, 10, 12–15, 18–20, 22–28, 30, 31, 33, 35, 37–39, 41, 43], followed by pulmonary involvement (60%) [6, 9–15, 17–19, 22–24, 26, 27, 29, 32, 33, 37–39, 41, 42] and renal disease (25%) [7, 10, 12, 14, 18, 19, 31, 34, 38, 42]. Isolated disease limited exclusively to the gynecological or lower urinary tract remained uncommon. Cervical involvement was the most frequently reported urogenital localization (45%) [6, 11, 13, 18, 23–28, 30–34, 36, 37, 43], followed by bladder and vaginal involvement, confirming that female genital tract GPA most commonly affects the uterine cervix and may closely mimic gynecological malignancy. Vaginal bleeding remained the predominant presenting symptom (40%) [6, 8, 16, 18, 21, 26–28, 30–37], often accompanied by pelvic pain, ulceration, or mass-like lesions on imaging. This clinical and radiological resemblance to cervical, bladder, or vulvar cancer frequently resulted in significant overtreatment, including radical and frequently unnecessary surgical procedures such as hysterectomy, cystectomy, or vulvectomy, often associated with substantial postoperative morbidity and permanent anatomical disfigurement. Immunologically, ANCA positivity was reported in most patients, predominantly as c-ANCA/PR3-ANCA, while ANCA-negative disease was uncommon. Several reports, however, lacked complete serological data, reflecting the diagnostic difficulty of localized or atypical presentations. Glucocorticoids remained the mainstay of treatment, most commonly combined with cyclophosphamide for remission induction. Rituximab was mainly used in refractory or relapsing cases, reflecting the growing role of biologic therapy in GPA management. Recent reports increasingly stress the importance of early recognition and multidisciplinary collaboration to avoid unnecessary radical surgery. The present patient illustrates many of these challenges: initial genitourinary presentation, strong suspicion of malignancy, multiple surgical interventions before diagnosis, and later development of typical ENT manifestations with c-ANCA positivity. This case highlights the need to consider GPA in the differential diagnosis of persistent inflammatory, ulcerative, or tumor-like lesions of the female urogenital tract, especially when histopathology is inconclusive. Discussion Our case highlights the diagnostic complexity and therapeutic challenges associated with granulomatosis with polyangiitis (GPA), particularly in patients presenting with non-classical organ involvement. The patient described herein demonstrated an unusual disease onset, initially manifesting with urogenital tract involvement, which is a rare and misleading presentation in GPA. The presence of a bladder mass with persistent clinical suspicion of malignancy resulted in a radical surgical intervention (Bricker cystectomy) prior to establishing the correct autoimmune etiology. Histopathological findings, including granulomatous inflammation and necrotizing vasculitis, were consistent with GPA, but were only retrospectively interpreted in the context of the patient’s evolving clinical picture. Urogenital manifestations of GPA remain underrecognized and are rarely the initial presenting symptom. Literature suggests that urogenital involvement occurs in < 2% of GPA patients [4]. Reported female presentations include pelvic inflammatory infiltrative lesions, adnexal masses, bladder lesions, ureteral stenosis, and genital ulcerations, frequently leading to diagnostic uncertainty and delayed recognition of vasculitis. In this case, the recurrent perineal and vaginal stump inflammation, together with systemic features and laboratory evidence of autoimmunity (e.g., PR3-ANCA positivity, elevated inflammatory markers), supported the diagnosis of limited-form GPA, despite the absence of classic respiratory or renal involvement at disease onset. The differential diagnosis in patients presenting with infiltrative pelvic and urogenital lesions is broad and includes both malignant and inflammatory conditions [44]. In the present case, the dominant clinical suspicion was urothelial malignancy due to the radiological appearance of the bladder mass and progressive infiltrative changes within the pelvis. However, repeated histopathological examinations failed to confirm neoplasia. Other conditions that may mimic GPA in this setting include chronic infections, inflammatory pseudotumors, and IgG4-related disease, particularly in cases characterized by fibrosis and mass-forming lesions [44]. In our patient, infectious etiologies including bacterial, fungal, and actinomycotic infection were excluded during the diagnostic work-up, while normal serum IgG4 levels and the presence of high-titer PR3-ANCA supported the diagnosis of ANCA-associated vasculitis. Over time, the disease evolved into a more characteristic systemic phenotype with sinonasal involvement, purpuric skin lesions, and peripheral neuropathy. The patient’s relapsing course, marked by multiple flares, affecting both typical and atypical organ systems, required escalation from conventional immunosuppressive agents (cyclophosphamide, methotrexate, azathioprine) to biological therapy. The introduction of rituximab, in line with current EULAR recommendations [45] for refractory or relapsing GPA, resulted in a significant clinical response and sustained remission. Available evidence regarding urogenital GPA remains limited largely to isolated case reports and small case series, which restricts the ability to establish standardized diagnostic and therapeutic approaches. Nonetheless, the principal strength of this study is the presentation of a rare clinical case contextualized within a summary of similar reports. This emphasizes the significant variability in the clinical manifestations of granulomatosis with polyangiitis (GPA) and underscores the importance of awareness among a broad range of medical specialists – not only rheumatologists – regarding the diverse presentations of this disease. Conclusions and future perspectives The presented case underscores the importance of maintaining a high index of suspicion for systemic vasculitis in patients with unexplained granulomatous inflammation, even when presenting in uncommon anatomical locations. Early involvement of rheumatology and appropriate serological testing can prevent unnecessary invasive procedures and guide timely immunosuppressive therapy. Moreover, this case highlights the crucial role of individualized treatment strategies and the efficacy of B-cell depletion therapy in patients with refractory disease. Further accumulation of similar cases may improve understanding of the clinical course and optimal management of urogenital GPA. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 2 Supplementary Material 3 Supplementary Material 4 Supplementary Material 5 Supplementary Material 6 Supplementary Material 7 Author contributions Conceptualization: AM (Anna Masiak); Data curation: NM (Natalia Muklewicz), IT (Ilona Tadulewicz); Formal Analysis: NM, IT, KS (Katarzyna Sienkiewicz), MK (Michał Kujach); Investigation: NM, IT, IA (Iwona Aponowicz), KS, MK; Methodology: NM, IT, AM; Project Administration: NM, IT, AM; Resources: IA, AM; Supervision: MC (Michał Chmielewski), AM; Validation: KS, MK, MC, AM; Visualization: NM, IT, KS, MK; Writing—original draft: NM, IT; Writing—review and editing: AM. All authors read and approved the final manuscript. Funding No funding was received for conducting this study. The authors have no relevant financial or non-financial interests to disclose. Declarations Conflict of interest The authors declare that there are no competing interests. Ethical approval Not applicable. Informed consent Informed consent for publication was obtained from the patient. No part of this correspondence item is copied or published elsewhere in whole or in part. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Natalia Muklewicz and Ilona Tadulewicz have contributed equally to this work. References Associated Data Supplementary Materials Supplementary Material 1 Supplementary Material 2 Supplementary Material 3 Supplementary Material 4 Supplementary Material 5 Supplementary Material 6 Supplementary Material 7